Owners, management and financials
CVR: 27347223
Secondary names: Orifarm Healthcare Holding A/S
Previous names: COPYFARM HOLDING A/S
DKK 459,463,000
Revenue
Net result: DKK 273,125,000
ORIFARM GROUP A/S (100%)
CVR · view owners
Thomas Brandhof
Board: Hans Carl Bøgh-Sørensen (chair) and 3 members
CVR · view management
Active
Founded 12 September 2003
CVR · view overview
0 employees
CVR · 2016
Director role ended: Ulrik Kronborg Markussen
CVR · 03/09/2025
View the full event history
ORIFARM GENERICS HOLDING A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2003. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named COPYFARM HOLDING A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GROUP A/S. The company has 0 employees (2016). In 2025, the company reported revenue of DKK 459,463,000 and a net result of DKK 273,125,000 compared with DKK 89,363,000 the year before. Equity in the 2025 report amounted to DKK 2,399,752,000.
Source: annual report 2025, Danish Business Authority
The financial health of ORIFARM GENERICS HOLDING A/S appears robust, highlighted by a significant increase in revenue to 459,463,000 DKK in 2025, alongside a gross profit of 467,921,000 DKK and a profit of 273,125,000 DKK. The company has shown a positive profit trend, with profits rising from 89,363,000 DKK in 2024 to 273,125,000 DKK in 2025, indicating strong operational performance. Equity has also grown substantially, reaching 2,399,752,000 DKK in 2025, which reflects a solid financial foundation. However, the lack of revenue data for previous years raises some concerns about transparency and consistent revenue generation. Overall, ORIFARM GENERICS is well-positioned in the non-financial holding sector, benefiting from strong profit margins and equity growth.
AI-generated summary · Generated 20/08/2026
Selskabets formål er at besidde kapitalandele i datterselskaberne og at erhverve og besidde immaterielle og materielle aktiver, som knytter sig til disse. Endvidere er selskabets formål at forestå forretningsudvikling og ledelsesmæssige opgaver for datterselskaber samt dertil beslægtede opgaver, der måtte forekomme i koncernen.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 459.5 mio. | 273.1 mio. | 3.4 mia. | 2.4 mia. | 0 | |
| 202401/01/2024 – 31/12/2024 | - | 89.4 mio. | 3.4 mia. | 2.1 mia. | - | |
| 202301/01/2023 – 31/12/2023 | - | 91.8 mio. | 3.5 mia. | 2.2 mia. | - | |
| 202201/01/2022 – 31/12/2022 | - | 130.3 mio. | 3.7 mia. | 2.1 mia. | 0 | |
| 202101/01/2021 – 31/12/2021 | - | 213.1 mio. | 3.2 mia. | 2.5 mia. | - | |
| 202001/01/2020 – 31/12/2020 | - | 114.2 mio. | 627.6 mio. | 417.5 mio. | 0 | |
| 201901/01/2019 – 31/12/2019 | 0 EUR | 9.7 mio. EUR | 68.9 mio. EUR | 40.6 mio. EUR | 204 | |
| 201801/01/2018 – 31/12/2018 | - | 5.5 mio. EUR | 67.7 mio. EUR | 35.9 mio. EUR | 203 | |
| 201701/01/2017 – 31/12/2017 | - | 8.5 mio. EUR | 69.2 mio. EUR | 38.5 mio. EUR | 188 | |
| 201601/01/2016 – 31/12/2016 | - | 9 mio. EUR | 66.1 mio. EUR | 35 mio. EUR | 165 | |
| 201501/01/2015 – 31/12/2015 | - | 5.2 mio. | 492 mio. | 194.3 mio. | - | |
| 201401/01/2014 – 31/12/2014 | - | 4.1 mio. | 45 mio. | 15.3 mio. | - | |
| 201301/01/2013 – 31/12/2013 | - | -150 t. | 50 mio. | 11.5 mio. | - | |
| 201201/01/2012 – 31/12/2012 | - | 7.1 mio. | 38.7 mio. | 12 mio. | - |
Compared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of ORIFARM GENERICS HOLDING A/S is 27347223.
ORIFARM GENERICS HOLDING A/S is owned by ORIFARM GROUP A/S.
The management of ORIFARM GENERICS HOLDING A/S consists of Thomas Brandhof.
The board of ORIFARM GENERICS HOLDING A/S consists of Hans Carl Bøgh-Sørensen, Birgitte Bøgh-Sørensen and Mads Fink Eriksen, with Hans Carl Bøgh-Sørensen as chair.
In 2025, ORIFARM GENERICS HOLDING A/S reported revenue of DKK 459,463,000.
ORIFARM GENERICS HOLDING A/S had 0 employees in 2016 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2025. Revenue came to DKK 459,463,000, and the net result was DKK 273,125,000.
Contact info changed: new phone: 63952800 (February 23, 2026).
As of October 20, 2025, Nicki Lund Kristensen has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of September 3, 2025, Thomas Brandhof is registered as adm. dir. of ORIFARM GENERICS HOLDING A/S.
As of September 3, 2025, Ulrik Kronborg Markussen has stepped down as adm. dir. of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2024. Gross profit came to DKK 243,237,000, and the net result was DKK 89,363,000.
As of March 17, 2025, Mads Fink Eriksen has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 17, 2025, Erik Sandberg has left the board of directors of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2023. Gross profit came to DKK 326,755,000, and the net result was DKK 91,843,000.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2022. Gross profit came to DKK 309,186,000, and the net result was DKK 130,350,000.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2021. Gross profit came to DKK 190,643,000, and the net result was DKK 213,053,000.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2020. Gross profit came to DKK 12,868,000, and the net result was DKK 114,171,000.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK 9,696,000.
As of August 26, 2019, Ulrik Kronborg Markussen is registered as adm. dir. of ORIFARM GENERICS HOLDING A/S.
As of August 26, 2019, Karsten Haumann has stepped down as adm. dir. of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2018. Gross profit came to DKK 846,000, and the net result was DKK 5,504,000.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2017. Gross profit came to DKK 701,000, and the net result was DKK 8,507,000.
As of May 15, 2018, Karsten Haumann is registered as adm. dir. of ORIFARM GENERICS HOLDING A/S.
As of May 15, 2018, Ulrik Ernst Rasmussen has stepped down as adm. dir. of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2016. Gross profit came to DKK 1,010,000, and the net result was DKK 9,035,000.
As of July 4, 2016, Birgitte Bøgh-Sørensen has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of July 4, 2016, Peter Arend William Burema has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of July 4, 2016, Claudio Albrecht has left the board of directors of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2015. Gross profit came to DKK 5,654,000, and the net result was DKK 5,160,000.
As of May 31, 2016, Claus Christian Bayer has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of May 31, 2016, Rolf Eckersberg has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of August 26, 2015, Claus Christian Bayer has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of August 26, 2015, Rolf Eckersberg has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2014. Gross profit came to DKK 8,233,000, and the net result was DKK 4,116,000.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2013. Gross profit came to DKK 6,792,000, and the net result was DKK -150,000.
As of May 20, 2014, Jean-Francois Loumeau has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of May 13, 2014, Claudio Albrecht has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of May 13, 2014, Hans Christian Eberhard Groth Teisen has left the board of directors of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2012. Gross profit came to DKK 13,109,000, and the net result was DKK 7,089,000.
As of March 4, 2013, Hans Christian Eberhard Groth Teisen has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Erik Sandberg has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Peter Arend William Burema has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Jean-Francois Loumeau has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Ole Michael Friis has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Claus Christian Bayer has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Ulrik Ernst Rasmussen is registered as adm. dir. of ORIFARM GENERICS HOLDING A/S.
As of March 4, 2013, Hans Carl Bøgh-Sørensen has stepped down as adm. dir. of ORIFARM GENERICS HOLDING A/S.
As of October 13, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ORIFARM GENERICS HOLDING A/S.
As of October 13, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of ORIFARM GENERICS HOLDING A/S.
As of May 23, 2007, Claus Christian Bayer has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of May 23, 2007, Niels Harald de Coninck-Smith has left the board of directors of ORIFARM GENERICS HOLDING A/S.
On April 30, 2007, the company changed its name from COPYFARM HOLDING A/S to ORIFARM GENERICS HOLDING A/S.
As of May 23, 2006, Niels Harald de Coninck-Smith has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of May 23, 2006, Jan Johannes Wøidemann has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of September 13, 2004, ORIFARM GROUP A/S is registered as an owner of ORIFARM GENERICS HOLDING A/S with an ownership share of 100%.
As of September 10, 2004, Hans Carl Bøgh-Sørensen is registered as adm. dir. of ORIFARM GENERICS HOLDING A/S.
As of September 12, 2003, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of ORIFARM GENERICS HOLDING A/S.
As of September 12, 2003, Ole Michael Friis has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of September 12, 2003, Jan Johannes Wøidemann has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S was founded on September 12, 2003.
Companies in the same industry and area
CVR 38767534
CVR 45086259
CVR 34052530
CVR 29778604
CVR 40044302
